Current Report Filing (8-k)
May 26 2020 - 4:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May
19, 2020
SONOMA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-33216
|
|
68-0423298
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
1129 N. McDowell Blvd.
Petaluma, CA 94954
(Address of principal executive offices)
(Zip Code)
(707) 283-0550
(Registrant’s telephone number, including
area code)
Not applicable.
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
Common stock
|
SNOA
|
The Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth
company o
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
|
Item 1.01
|
Entry into a Material Definitive Agreement.
|
On May 19, 2020, we entered into a new
license and distribution agreement with our existing partner Brill International S.L. for our Microdacyn60® Eye Care product
based on our patented Microcyn® Technology. Under the new license and distribution agreement, Brill has the right to market
and distribute our eye care product under the private label Ocudox™ in Italy, Germany, Spain, Portugal, and the United Kingdom
for a period of 10 years, subject to meeting annual minimum sales quantities. In return, Brill will pay Sonoma a one-time fee on
April 1, 2021 and the agreed upon supply prices. Previously, under the old license and distribution agreement dated August 1, 2018,
Brill marketed our eye care product only in Spain and Portugal.
This report contains forward-looking
statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs,
expectations, strategies, predictions or any other statements related to our future activities or future events or
conditions. These statements are based on current expectations, estimates and projections about our business based, in part,
on assumptions made by management. These statements are not guarantees of future performances and involve risks,
uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ
materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those
risks discussed in our Annual Report on Form 10-K and in other documents that we file from time to time with the
SEC. Any forward-looking statements speak only as of the date on which they are made, and we do not undertake any
obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except
as required by law.
Item 9.01. Financial
Statements and Exhibits.
† Certain
portions of the Agreement have been omitted to preserve the confidentiality of such information. The Company will furnish copies
of any such information to the SEC upon request.
*
The exhibits or schedules to the Agreement have been omitted from this filing
pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish copies of any such schedules to the SEC
upon request.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Sonoma Pharmaceuticals, Inc.
|
|
(Registrant)
|
|
|
Date: May 26, 2020
|
By:
|
/s/ Amy Trombly
|
|
Name:
Title:
|
Amy Trombly
Chief Executive Officer
|
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Sep 2023 to Sep 2024